CellaVision AB (CEVI) - Net Assets

Latest as of December 2025: Skr887.58 Million SEK ≈ $95.52 Million USD

Based on the latest financial reports, CellaVision AB (CEVI) has net assets worth Skr887.58 Million SEK (≈ $95.52 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr1.09 Billion ≈ $117.83 Million USD) and total liabilities (Skr207.31 Million ≈ $22.31 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CEVI asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Skr887.58 Million
% of Total Assets	81.07%
Annual Growth Rate	10.91%
5-Year Change	63.37%
10-Year Change	330.5%
Growth Volatility	42.35

CellaVision AB - Net Assets Trend (2000–2025)

This chart illustrates how CellaVision AB's net assets have evolved over time, based on quarterly financial data. Also explore total assets of CellaVision AB for the complete picture of this company's asset base.

Annual Net Assets for CellaVision AB (2000–2025)

The table below shows the annual net assets of CellaVision AB from 2000 to 2025. For live valuation and market cap data, see CEVI market cap.

Year	Net Assets	Change
2025-12-31	Skr887.58 Million ≈ $95.52 Million	+8.81%
2024-12-31	Skr815.73 Million ≈ $87.79 Million	+13.87%
2023-12-31	Skr716.39 Million ≈ $77.09 Million	+11.65%
2022-12-31	Skr641.63 Million ≈ $69.05 Million	+18.10%
2021-12-31	Skr543.28 Million ≈ $58.47 Million	+26.46%
2020-12-31	Skr429.62 Million ≈ $46.23 Million	+23.32%
2019-12-31	Skr348.37 Million ≈ $37.49 Million	+19.97%
2018-12-31	Skr290.38 Million ≈ $31.25 Million	+20.56%
2017-12-31	Skr240.85 Million ≈ $25.92 Million	+16.82%
2016-12-31	Skr206.18 Million ≈ $22.19 Million	+12.35%
2015-12-31	Skr183.52 Million ≈ $19.75 Million	+21.30%
2014-12-31	Skr151.30 Million ≈ $16.28 Million	+14.17%
2013-12-31	Skr132.52 Million ≈ $14.26 Million	+6.09%
2012-12-31	Skr124.91 Million ≈ $13.44 Million	-0.92%
2011-12-31	Skr126.07 Million ≈ $13.57 Million	+11.15%
2010-12-31	Skr113.42 Million ≈ $12.21 Million	+51.64%
2009-12-31	Skr74.80 Million ≈ $8.05 Million	+62.66%
2008-12-31	Skr45.98 Million ≈ $4.95 Million	+129.10%
2007-12-31	Skr20.07 Million ≈ $2.16 Million	+13.19%
2006-12-31	Skr17.73 Million ≈ $1.91 Million	-33.24%
2005-12-31	Skr26.56 Million ≈ $2.86 Million	+46.36%
2004-12-31	Skr18.15 Million ≈ $1.95 Million	+124.91%
2003-12-31	Skr8.07 Million ≈ $868.35K	-83.42%
2002-12-31	Skr48.66 Million ≈ $5.24 Million	-41.09%
2001-12-31	Skr82.60 Million ≈ $8.89 Million	+23.90%
2000-12-31	Skr66.67 Million ≈ $7.17 Million	--

Equity Component Analysis

This analysis shows how different components contribute to CellaVision AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Other Components	Skr887.58 Million	100.00%
Total Equity	Skr887.58 Million	100.00%

CellaVision AB Competitors by Market Cap

The table below lists competitors of CellaVision AB ranked by their market capitalization.

Company	Market Cap
Medios AG XETRA:ILM1	$311.23 Million
United Malacca Bhd KLSE:2593	$311.26 Million
Yunnan Bowin Technology Industry Co Ltd SHG:600883	$311.27 Million
Xinjiang Youhao Group Co Ltd SHG:600778	$311.32 Million
K&F Growth Acquisition Corp. II Class A Ordinary shares NASDAQ:KFII	$310.97 Million
Know Labs Inc. NYSE MKT:KNW	$310.88 Million
Canada Nickel Company Inc V:CNC	$310.82 Million
Maritima De In SN:MARINSA	$310.82 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in CellaVision AB's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 815,726,000 to 887,578,000, a change of 71,852,000 (8.8%).
Net income of 153,078,000 contributed positively to equity growth.
Dividend payments of 59,629,000 reduced retained earnings.
Other comprehensive income decreased equity by 29,733,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Skr153.08 Million	+17.25%
Dividends Paid	Skr59.63 Million	-6.72%
Other Comprehensive Income	Skr-29.73 Million	-3.35%
Other Changes	Skr8.14 Million	+0.92%
Total Change	Skr-	8.81%

Book Value vs Market Value Analysis

This analysis compares CellaVision AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 3.26x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 144.02x to 3.26x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2007-12-31	Skr0.84	Skr121.20	x
2008-12-31	Skr1.93	Skr121.20	x
2009-12-31	Skr3.14	Skr121.20	x
2010-12-31	Skr4.76	Skr121.20	x
2011-12-31	Skr5.29	Skr121.20	x
2012-12-31	Skr5.24	Skr121.20	x
2013-12-31	Skr5.56	Skr121.20	x
2014-12-31	Skr6.34	Skr121.20	x
2015-12-31	Skr7.69	Skr121.20	x
2016-12-31	Skr8.64	Skr121.20	x
2017-12-31	Skr10.10	Skr121.20	x
2018-12-31	Skr12.17	Skr121.20	x
2019-12-31	Skr14.61	Skr121.20	x
2020-12-31	Skr18.01	Skr121.20	x
2021-12-31	Skr22.78	Skr121.20	x
2022-12-31	Skr26.90	Skr121.20	x
2023-12-31	Skr30.03	Skr121.20	x
2024-12-31	Skr34.20	Skr121.20	x
2025-12-31	Skr37.21	Skr121.20	x

Capital Efficiency Dashboard

This dashboard shows how efficiently CellaVision AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 17.25%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 20.17%
• Asset Turnover: 0.69x
• Equity Multiplier: 1.23x
Recent ROE (17.25%) is below the historical average (23.74%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2007	13.08%	3.52%	1.69x	2.20x	Skr617.80K
2008	54.48%	24.94%	1.04x	2.10x	Skr20.46 Million
2009	37.06%	25.44%	0.96x	1.52x	Skr20.24 Million
2010	33.81%	29.13%	0.81x	1.43x	Skr27.01 Million
2011	11.61%	9.42%	0.87x	1.42x	Skr2.03 Million
2012	5.16%	3.81%	0.95x	1.43x	Skr-6.04 Million
2013	14.29%	10.53%	0.95x	1.42x	Skr5.68 Million
2014	20.80%	14.51%	1.07x	1.34x	Skr16.34 Million
2015	28.78%	22.07%	1.09x	1.20x	Skr34.47 Million
2016	29.00%	22.56%	1.03x	1.24x	Skr39.18 Million
2017	28.95%	22.54%	1.03x	1.25x	Skr45.64 Million
2018	30.54%	24.31%	0.98x	1.28x	Skr59.65 Million
2019	28.47%	21.48%	0.72x	1.84x	Skr64.33 Million
2020	20.83%	18.98%	0.71x	1.55x	Skr46.52 Million
2021	23.07%	22.16%	0.69x	1.52x	Skr71.01 Million
2022	18.44%	18.51%	0.72x	1.39x	Skr54.17 Million
2023	18.19%	19.24%	0.73x	1.30x	Skr58.67 Million
2024	17.25%	19.46%	0.71x	1.24x	Skr59.15 Million
2025	17.25%	20.17%	0.69x	1.23x	Skr64.32 Million

Industry Comparison

This section compares CellaVision AB's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

Industry: Medical Devices
Average net assets among peers: $92,010,697
Average return on equity (ROE) among peers: -32.93%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
CellaVision AB (CEVI)	Skr887.58 Million	13.08%	0.23x	$311.10 Million
Acarix A/S (ACARIX)	$15.12 Million	-127.02%	0.21x	$33.84 Million
Arcoma AB (ARCOMA)	$48.66 Million	5.27%	0.68x	$11.55 Million
Bactiguard Holding AB (publ) (BACTI-B)	$387.11 Million	-0.84%	0.62x	$61.64 Million
BICO Group AB (BICO)	$2.31 Million	0.00%	2.47x	$159.82 Million
Boule Diagnostics AB (BOUL)	$295.74 Million	7.87%	0.93x	$14.38 Million
Clinical Laserthermia Systems AB (publ) (CLS-B)	$26.09 Million	-70.24%	0.12x	$11.57 Million
Chordate Medical Holding AB (CMH)	$25.64 Million	-77.06%	0.22x	$29.05K
C-Rad AB (publ) (CRAD-B)	$29.82 Million	-34.38%	0.50x	$86.08 Million
Duearity AB (DEAR)	$-2.39 Million	0.00%	0.00x	$331.97K

About CellaVision AB

ST:CEVI Sweden Medical Devices

Market Cap

$311.10 Million

Skr2.89 Billion SEK

Market Cap Rank

#14799 Global

#231 in Sweden

Share Price

Skr121.20

Change (1 day)

-1.14%

52-Week Range

Skr120.20 - Skr200.00

All Time High

Skr478.48